Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company using a "Precision Psychiatry Platform" to develop targeted treatments for depression, schizophrenia, and other neuropsychiatric disorders. With no commercial revenue yet and a pipeline dominated by a single lead asset, the stock's valuation hinges almost entirely on clinical-trial outcomes — which is why a central price target of roughly $40 sits well above the current share price.
Roughly 11 current analyst price targets were reviewed, spanning from about $26 on the cautious end to $60 on the bullish end. The arithmetic mean works out to approximately $38.67, which is rounded to a $40 central target for this analysis. It is important to note that this is a calculated average of individual targets, not an official published consensus.
The spread tells the story. H.C. Wainwright's Patrick Trucchio raised his target to $60 from $55 in October 2026, arguing that independent pramipexole data support ALTO-207's mechanism and that the three-trial PACE program could broaden the drug's indication. Bank of America and Jefferies each moved targets into the $40 area in August 2026, while BTIG lifted its target to $37. At the other end, Wedbush holds a Neutral rating with a target near $26, reflecting a more conservative view of the clinical and execution risk. The gap between the top and bottom targets underscores that analysts broadly agree on the opportunity but disagree sharply on how much of it is already priced in.
Shares have recently traded near $28, within a 52-week range of roughly $10.80 to $37.48. Reaching the $40 central target would therefore require a gain of about 43%, which is a substantial move for a pre-revenue company whose value is tied to data releases rather than quarterly results.
The path toward that level is event-driven rather than earnings-driven. Alto reported a third-quarter 2026 net loss of $25.1 million, or $0.54 per share, and closed the quarter with roughly $319.8 million in cash, cash equivalents, and restricted cash — funding the company expects to carry it through 2030. The lead asset, ALTO-207 (a modified-release combination of pramipexole and ondansetron) for treatment-resistant depression, has topline data from its PACE-1 Phase 2b trial expected in the second half of 2027, with Phase 3 studies planned around it. Positive readouts on ALTO-300 (major depressive disorder, first half of 2027) and ALTO-100 (bipolar depression, mid-2027) could also re-rate the shares.
The shares remain well below the 52-week high near $37.48, which now functions as a meaningful resistance zone on any advance toward $40. The psychologically important $40 level sits just above that prior high, so a move to the central target would likely require breaking through both. On the downside, the 52-week low near $10.80 is distant, but the stock's history of sharp, news-driven swings means that support is defined more by financing milestones and data catalysts than by stable technical floors.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state a uniform timeframe. Investors should watch the late-2026/early-2027 FDA interaction and Phase 1 formulation data for ALTO-207, the initiation of the PACE-2 Phase 3 trial in early 2027, and the ALTO-300 and ALTO-100 Phase 2b readouts later in 2027. Quarterly cash burn, analyst revisions around each data event, and any regulatory feedback will be the key drivers of the stock's trajectory.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a catalyst-heavy name like Alto Neuroscience, where price action can shift rapidly around trial news, such signals can help traders spot changing trends, monitor positions, and surface opportunities more efficiently. Traders looking to complement their fundamental research with automated, data-driven timing may find the tool a useful addition to their workflow.
The question of whether Alto Neuroscience can reach $40 rests less on financial performance than on clinical execution. The central target is a calculated average of analyst price targets spanning roughly $26 to $60, and the roughly 43% required move is substantial. A strengthened cash position and a busy 2027 catalyst calendar provide the foundation for bullish targets, while the absence of revenue and the binary nature of trial outcomes are the principal obstacles. With no way to know in advance how the data will read, investors should treat the target as a reflection of analyst expectations rather than a forecast, and focus on the upcoming regulatory interactions and trial readouts that will ultimately determine the stock's path.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with MLYS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then MLYS could also see price increases.
| Ticker / NAME | Correlation To ANRO | 1D Price Change % | ||
|---|---|---|---|---|
| ANRO | 100% | +2.91% | ||
| MLYS - ANRO | 40% Loosely correlated | -1.83% | ||
| LXEO - ANRO | 38% Loosely correlated | -2.55% | ||
| EDIT - ANRO | 38% Loosely correlated | -8.91% | ||
| PTGX - ANRO | 38% Loosely correlated | +0.26% | ||
| VERA - ANRO | 38% Loosely correlated | -1.89% | ||
More | ||||